COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells

OMICS A Journal of Integrative Biology

Volumn 15, Issue 6, 2011, Pages 383-392

  Cervello, Melchiorre ^a   Bachvarov, Dimcho ^b,c   Cusimano, Antonella ^a   Sardina, Francesca ^a   Azzolina, Antonina ^a   Lampiasi, Nadia ^a   Giannitrapani, Lydia ^d   McCubrey, James A ^e   Montalto, Giuseppe ^d  

^a CNR   (Italy)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITY OF PALERMO   (Italy)

^e EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; ENERGY METABOLISM; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIPID METABOLISM; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TURNOVER TIME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSCRIPTION, GENETIC;

EID: 79958705324     PISSN: 15362310     EISSN: 15362310     Source Type: Journal    
DOI: 10.1089/omi.2010.0092     Document Type: Article

References (26)

1. Bachvarov, D., L'Espérance, S., Popa, I., Bachvarova, M., Plante, M., and Têtu, B. (2006). Gene expression patterns of chemo-resistant and chemosensitive ovarian serous adenocarcinomas with possible prognostic value in response to initial chemotherapy. Int J Oncol 29, 919-933.
2. Cai, L., Fritz, D., Stefanovic, L., and Stefanovic, B. (2009). Coming together: liver fibrosis, collagen mRNAs and the RNA binding protein. Exp Rev Gastroenterol Hepatol 3, 1-3.
3. 0 stem-loop regulates translation of mRNAs encoding type I collagen. J Mol Biol 395, 309-326.
4. Cervello, M., Notarbartolo, M., Landino, M., Cusimano, A., Virruso, L., Montalto, G., et al. (2001). Downregulation of wild-type b-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effects of the cytokine? Eur J Cancer 37, 512-519. (Pubitemid 32232117)
5. Cervello, M., Giannitrapani, L., Labbozzetta, M., Notarbartolo, M., D'Alessandro, N., Lampiasi, N., et al. (2004). Expression of WISPs and of their novel alternative variants in human he-patocellular carcinoma cells. Ann NY Acad Sci 1028, 432-439. (Pubitemid 40361844)
6. Cusimano, A., Azzolina, A., Iovanna, J.L., Bachvarov, D., McCubrey, J.A., D'Alessandro, N., et al. (2010). Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle 9, 1399-1410.
7. Fedi, P., Bafico, A., Nieto Soria, A., Burgess, W.H., Miki, T., Bottaro, D.P., et al. (1999). Isolation and biochemical characterization of the human DKKK1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 274, 19465-19472.
8. Foderà, D., D'Alessandro, N., Cusimano, A., Poma, P., Notarbartolo, M., Lampiasi, N., et al. (2004). Induction of apoptosis and inhibition of cell growth in human hepatocel-lular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci 1028, 440-449. (Pubitemid 40361845)
9. Funakoshi-Tago, M., Shimizu, T., Tago, K., Nakamura, M., Itoh, H., Sonoda, Y., et al. (2008). Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB. Biochem Pharmacol 76, 662-671.
10. Grosch, S., Tegeder, I., Niederberger, E., Brautigam, L., and Geisslinger, G. (2001). COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15, 2742-2744.
11. Kashfi, K., and Rigas, B. (2005). Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemopreven-tion. Biochem Pharmacol 70, 969-986. (Pubitemid 41262072)
12. Kern, M.A., Schubert, D., Sahi, D., Schöneweiss, M.M., Moll, I., Haugg, A.M., et al. (2002). Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36, 885-894.
13. Lampiasi, N., Foderà, D., D'Alessandro, N., Cusimano, A., Azzolina, A., Tripodo, C., et al. (2006). The selective cycloox-ygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Mol Med 17, 245-252.
14. Lampiasi, N., Azzolina, A., D'Alessandro, N., Umezawa, K., McCubrey, J.A., Montalto, G., et al. (2009). Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. Mol Pharmacol 76, 290-300.
15. Leng, J., Han, C., Demetris, A.J., Michalopoulos, G.K., and Wu, T. (2003). Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38, 756-768. (Pubitemid 37052162)
16. L'Espérance, S., Popa, I., Bachvarova, M., Plante, M., Patten, N., Wu, L., et al. (2006). Gene expression profiling of paired tumor samples obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 29, 5-24.
17. Llovet, J.M. and Bruix, J. (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48,1312-1327.
18. Marquez-Rosado, L., Trejo-Solis, M.C., Garcia-Cuellar, C.M., and Villa-Trevino, S. (2005). Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J Hepatol 43, 653-660. (Pubitemid 41253233)
19. Montalto, G., Cervello, M., Giannitrapani, L., Dantona, F., Ter-ranova, A., and Castagnetta, L.M. (2002). Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 963, 13-20. (Pubitemid 34721691)
20. Nakamura, M., Shimada, K., and Konishi, N. (2009). The role of HRK gene in human cancer. Oncogene 27, S105-S113.
21. Sherman, M. (2010). Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 30, 3-16.
22. Subhashini, J., Mahipal, S.V., and Reddanna, P. (2005). Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett 224, 31-43. (Pubitemid 40720365)
23. Wang, S.M., Ooi, L.L., and Hui, K.M. (2007). Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 13, 6275-6283. (Pubitemid 350075015)
24. Xu, M.Z., Yao, T.J., Lee, N.P., Ng, I.O., Chan, Y.T., Zender, L., et al. (2009). Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115, 4576-4585.
25. Yee, K.S., and O'Neill, E. (2010). YAP1: friend and foe. Cell Cycle 9, 1447-1448.
26. Yu, B., Yang, X., Xu, Y., Yao, G., Shu, H., Lin, B., et al. (2009). Elevated expression of DKK1 is associated with cytoplasmic/ nuclear beta-catenin accumulation and poor prognosis in he-patocellular carcinomas. J Hepatol 50, 948-957.